Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Duvelisib

(Copiktra®)

Duvelisib

Drug updated on 12/11/2024

Dosage FormCapsule (oral; 15 mg, 25 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Duvelisib demonstrated an overall response rate (ORR) of 70% in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell indolent non-Hodgkin lymphoma (iNHL), while patients with B-cell aggressive non-Hodgkin lymphoma (aNHL) had an ORR of 28% and T-cell non-Hodgkin lymphoma (T-NHL) had an ORR of 47%.
  • In subgroup analysis, mantle cell lymphoma (MCL) had a significantly higher ORR compared to other aggressive NHL (68% vs. 17%, p=0.04), and angioimmunoblastic T-cell lymphoma (AITL) showed a significantly higher ORR compared to other peripheral T-cell lymphomas (67% vs. 42%, p=0.01).
  • Comparative effectiveness between duvelisib and other PI3K inhibitors showed no statistically significant differences in ORR between duvelisib (48%) and other agents, such as idelalisib (43%, p=0.16) and copanlisib (49%, p=0.11).
  • Duvelisib was associated with a high incidence of any-grade adverse events (AEs) at 99%, with 79% experiencing grade ≥3 AEs, and 63% reporting serious AEs. The most common any-grade AEs were diarrhea (47%), ALT/AST increase (39%), and neutropenia (38%), while the most frequent grade ≥3 AEs included neutropenia (25%), ALT/AST increase (16%), and diarrhea (12%).
  • The risk of grade ≥3 treatment-emergent adverse events (TEAEs) was lower for tazemetostat compared to duvelisib (RR = 0.35, p < 0.01), idelalisib, copanlisib, and umbralisib.
  • Subgroup analysis showed significant differences in ORR for mantle cell lymphoma (MCL) compared to other aggressive non-Hodgkin lymphomas (68% vs. 17%, p=0.04) and angioimmunoblastic T-cell lymphoma (AITL) compared to other peripheral T-cell lymphomas (67% vs. 42%, p=0.01), while no significant difference in ORR was observed in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with or without TP53 mutation/17p-deletion (62% vs. 74%, p=0.45).